Crinetics Pharmaceuticals, Inc. (CRNX) [Rocket]

Overview

Crinetics Pharmaceuticals, Inc. (CRNX)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
08/16/2023	4	Struthers Richard Scott (President & CEO) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.
08/08/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/08/2023	8-K	Quarterly results
07/13/2023	4	Struthers Richard Scott (President & CEO) has filed a Form 4 on Crinetics Pharmaceuticals, Inc.
07/13/2023	144	Form 144 - Report of proposed sale of securities:
07/12/2023	144	Form 144 - Report of proposed sale of securities:
07/11/2023	144	Form 144 - Report of proposed sale of securities:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17
Revenues	0.0	135.0	0.0	85.3	0.1	1.2	2.4	2.0
Revenue growth		58.2%	-100.0%		-94.0%	-50.9%	18.7%	247.2%
Cost of goods sold	0.0	172.6	0.0	108.8	0.0	0.0	0.0	0.0
Gross profit	0.0	-37.7	0.0	-23.4	0.1	1.2	2.4	2.0
Gross margin		-27.9%		-27.5%	100.0%	100.0%	100.0%	100.0%
Selling, general and administrative	172.6		108.8		75.0	55.0
Research and development							24.5	9.2
General and administrative		42.4		24.5			6.7	1.9
EBIT	-160.0	-168.9	-107.6	-107.7	-73.8	-50.4	-28.7	-9.1
EBIT margin		-125.1%		-126.2%	-103984.5%	-4226.8%	-1182.5%	-446.3%
Pre-tax income	-163.9	0.0	-107.6	0.0	-73.8	-50.4	-27.1	-9.2
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%		0.0%		0.0%	0.0%	0.0%	0.0%
Net income	-163.9	0.0	-107.6	0.0	-73.8	-50.4	-27.1	-9.2
Net margin		0.0%		0.0%	-103960.6%	-4226.5%	-1116.8%	-447.8%

Diluted EPS	($3.15)	$0.00	($2.80)	$0.00	($2.42)	($2.09)	($2.23)	($6.68)
Shares outstanding (diluted)	52.0	52.0	38.4	38.4	30.4	24.2	12.1	1.4

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.